BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 17635717)

  • 1. Structure of fibrin: impact on clot stability.
    Weisel JW
    J Thromb Haemost; 2007 Jul; 5 Suppl 1():116-24. PubMed ID: 17635717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis.
    Collet JP; Moen JL; Veklich YI; Gorkun OV; Lord ST; Montalescot G; Weisel JW
    Blood; 2005 Dec; 106(12):3824-30. PubMed ID: 16091450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of actin filaments on fibrin clot structure and lysis.
    Janmey PA; Lamb JA; Ezzell RM; Hvidt S; Lind SE
    Blood; 1992 Aug; 80(4):928-36. PubMed ID: 1323346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones.
    Longstaff C; Varjú I; Sótonyi P; Szabó L; Krumrey M; Hoell A; Bóta A; Varga Z; Komorowicz E; Kolev K
    J Biol Chem; 2013 Mar; 288(10):6946-56. PubMed ID: 23293023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism.
    Martinez MR; Cuker A; Mills AM; Crichlow A; Lightfoot RT; Chernysh IN; Nagaswami C; Weisel JW; Ischiropoulos H
    Am J Physiol Lung Cell Mol Physiol; 2014 Mar; 306(5):L397-404. PubMed ID: 24414255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen.
    Hugenholtz GC; Macrae F; Adelmeijer J; Dulfer S; Porte RJ; Lisman T; Ariëns RA
    J Thromb Haemost; 2016 May; 14(5):1054-66. PubMed ID: 26833718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for the Investigation of Plasma and Whole Blood Clot Property of Fibrin Fiber Thickness Using Scanning Electron Microscopy.
    Cai T; McCafferty C; Van Den Helm S; Letunica N; Attard C; Monagle P; Ignjatovic V
    Methods Mol Biol; 2023; 2663():775-786. PubMed ID: 37204752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal antibody to the fibrinogen gamma-chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles.
    Scheiner T; Jirousková M; Nagaswami C; Coller BS; Weisel JW
    J Thromb Haemost; 2003 Dec; 1(12):2594-602. PubMed ID: 14675095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fracture toughness of fibrin gels as a function of protein volume fraction: Mechanical origins.
    Garyfallogiannis K; Ramanujam RK; Litvinov RI; Yu T; Nagaswami C; Bassani JL; Weisel JW; Purohit PK; Tutwiler V
    Acta Biomater; 2023 Mar; 159():49-62. PubMed ID: 36642339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate.
    Weisel JW; Litvinov RI
    Cardiovasc Hematol Agents Med Chem; 2008 Jul; 6(3):161-80. PubMed ID: 18673231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lytic Susceptibility, Structure, and Mechanical Properties of Fibrin in Systemic Lupus Erythematosus.
    Litvinov RI; Nabiullina RM; Zubairova LD; Shakurova MA; Andrianova IA; Weisel JW
    Front Immunol; 2019; 10():1626. PubMed ID: 31379831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescently conjugated annular fibrin clot for multiplexed real-time digestion analysis.
    Zeng Z; Nallan Chakravarthula T; Muralidharan C; Hall A; Linnemann AK; Alves NJ
    J Mater Chem B; 2021 Nov; 9(45):9295-9307. PubMed ID: 34698753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
    Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
    Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood clot contraction differentially modulates internal and external fibrinolysis.
    Tutwiler V; Peshkova AD; Le Minh G; Zaitsev S; Litvinov RI; Cines DB; Weisel JW
    J Thromb Haemost; 2019 Feb; 17(2):361-370. PubMed ID: 30582674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow affects the structural and mechanical properties of the fibrin network in plasma clots.
    Eyisoylu H; Hazekamp ED; Cruts J; Koenderink GH; de Maat MPM
    J Mater Sci Mater Med; 2024 Jan; 35(1):8. PubMed ID: 38285167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased fibrinolytic potential and morphological changes of fibrin structure in dermatitis herpetiformis.
    Görög A; Németh K; Szabó L; Mayer B; Silló P; Kolev K; Kárpáti S
    J Dermatol Sci; 2016 Oct; 84(1):17-23. PubMed ID: 27440075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The α-helix to β-sheet transition in stretched and compressed hydrated fibrin clots.
    Litvinov RI; Faizullin DA; Zuev YF; Weisel JW
    Biophys J; 2012 Sep; 103(5):1020-7. PubMed ID: 23009851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
    Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
    Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of fibrin structure in thrombosis and vascular disease.
    Cilia La Corte AL; Philippou H; Ariëns RA
    Adv Protein Chem Struct Biol; 2011; 83():75-127. PubMed ID: 21570666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.